Pfizer announces positive results from Phase 3 Study of Abrysvo
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
The Product is expected to be the first generic approval on the market
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
International Business is expected to register double-digit growth in constant currency terms
Subscribe To Our Newsletter & Stay Updated